Try a new search

Format these results:

Searched for:

in-biosketch:yes

person:bersha03

Total Results:

110


Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial

Barnabas, Ruanne V; Brown, Elizabeth R; Bershteyn, Anna; Stankiewicz Karita, Helen C; Johnston, Christine; Thorpe, Lorna E; Kottkamp, Angelica; Neuzil, Kathleen M; Laufer, Miriam K; Deming, Meagan; Paasche-Orlow, Michael K; Kissinger, Patricia J; Luk, Alfred; Paolino, Kristopher; Landovitz, Raphael J; Hoffman, Risa; Schaafsma, Torin T; Krows, Meighan L; Thomas, Katherine K; Morrison, Susan; Haugen, Harald S; Kidoguchi, Lara; Wener, Mark; Greninger, Alexander L; Huang, Meei-Li; Jerome, Keith R; Wald, Anna; Celum, Connie; Chu, Helen Y; Baeten, Jared M; ,
BACKGROUND:Effective prevention against coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently limited to nonpharmaceutical strategies. Laboratory and observational data suggested that hydroxychloroquine had biological activity against SARS-CoV-2, potentially permitting its use for prevention. OBJECTIVE:To test hydroxychloroquine as postexposure prophylaxis for SARS-CoV-2 infection. DESIGN:Household-randomized, double-blind, controlled trial of hydroxychloroquine postexposure prophylaxis. (ClinicalTrials.gov: NCT04328961). SETTING:National U.S. multicenter study. PARTICIPANTS:Close contacts recently exposed (<96 hours) to persons with diagnosed SARS-CoV-2 infection. INTERVENTION:Hydroxychloroquine (400 mg/d for 3 days followed by 200 mg/d for 11 days) or ascorbic acid (500 mg/d followed by 250 mg/d) as a placebo-equivalent control. MEASUREMENTS:Participants self-collected mid-turbinate swabs daily (days 1 to 14) for SARS-CoV-2 polymerase chain reaction (PCR) testing. The primary outcome was PCR-confirmed incident SARS-CoV-2 infection among persons who were SARS-CoV-2 negative at enrollment. RESULTS: = 0.026). LIMITATION:The delay between exposure, and then baseline testing and the first dose of hydroxychloroquine or ascorbic acid, was a median of 2 days. CONCLUSION:This rigorous randomized controlled trial among persons with recent exposure excluded a clinically meaningful effect of hydroxychloroquine as postexposure prophylaxis to prevent SARS-CoV-2 infection. PRIMARY FUNDING SOURCE:Bill & Melinda Gates Foundation.
PMID: 33284679
ISSN: 1539-3704
CID: 5865992

The risks and benefits of providing HIV services during the COVID-19 pandemic

Stover, John; Kelly, Sherrie L; Mudimu, Edinah; Green, Dylan; Smith, Tyler; Taramusi, Isaac; Bansi-Matharu, Loveleen; Martin-Hughes, Rowan; Phillips, Andrew N; Bershteyn, Anna
INTRODUCTION:The COVID-19 pandemic has caused widespread disruptions including to health services. In the early response to the pandemic many countries restricted population movements and some health services were suspended or limited. In late 2020 and early 2021 some countries re-imposed restrictions. Health authorities need to balance the potential harms of additional SARS-CoV-2 transmission due to contacts associated with health services against the benefits of those services, including fewer new HIV infections and deaths. This paper examines these trade-offs for select HIV services. METHODS:We used four HIV simulation models (Goals, HIV Synthesis, Optima HIV and EMOD) to estimate the benefits of continuing HIV services in terms of fewer new HIV infections and deaths. We used three COVID-19 transmission models (Covasim, Cooper/Smith and a simple contact model) to estimate the additional deaths due to SARS-CoV-2 transmission among health workers and clients. We examined four HIV services: voluntary medical male circumcision, HIV diagnostic testing, viral load testing and programs to prevent mother-to-child transmission. We compared COVID-19 deaths in 2020 and 2021 with HIV deaths occurring now and over the next 50 years discounted to present value. The models were applied to countries with a range of HIV and COVID-19 epidemics. RESULTS:Maintaining these HIV services could lead to additional COVID-19 deaths of 0.002 to 0.15 per 10,000 clients. HIV-related deaths averted are estimated to be much larger, 19-146 discounted deaths per 10,000 clients. DISCUSSION:While there is some additional short-term risk of SARS-CoV-2 transmission associated with providing HIV services, the risk of additional COVID-19 deaths is at least 100 times less than the HIV deaths averted by those services. Ministries of Health need to take into account many factors in deciding when and how to offer essential health services during the COVID-19 pandemic. This work shows that the benefits of continuing key HIV services are far larger than the risks of additional SARS-CoV-2 transmission.
PMCID:8699979
PMID: 34941876
ISSN: 1932-6203
CID: 5106292

Policy Review and Modeling Analysis of Mitigation Measures for Coronavirus Disease Epidemic Control, Health System, and Disease Burden, South Korea

Kim, Hae-Young; Oh, In-Hwan; Lee, Jacob; Seon, Jeong-Yeon; Jeon, Woo-Hwi; Park, Jae Seok; Nam, Sung-Il; Thakkar, Niket; Selvaraj, Prashanth; McGillen, Jessica; Klein, Daniel; Braithwaite, Scott; Bershteyn, Anna; Lee, Seung Heon
We reviewed the timeline of key policies for control of the coronavirus disease epidemic and determined their impact on the epidemic and hospital burden in South Korea. Using a discrete stochastic transmission model, we estimated that multilevel policies, including extensive testing, contact tracing, and quarantine, reduced contact rates by 90% and rapidly decreased the epidemic in Daegu and nationwide during February‒March 2020. Absence of these prompt responses could have resulted in a >10-fold increase in infections, hospitalizations, and deaths by May 15, 2020, relative to the status quo. The model suggests that reallocation of persons who have mild or asymptomatic cases to community treatment centers helped avoid overwhelming hospital capacity and enabled healthcare workers to provide care for more severely and critically ill patients in hospital beds and negative-pressure intensive care units. As small outbreaks continue to occur, contact tracing and maintenance of hospital capacity are needed.
PMCID:8544960
PMID: 34429188
ISSN: 1080-6059
CID: 5061082

Large age shifts in HIV-1 incidence patterns in KwaZulu-Natal, South Africa

Akullian, Adam; Vandormael, Alain; Miller, Joel C; Bershteyn, Anna; Wenger, Edward; Cuadros, Diego; Gareta, Dickman; Bärnighausen, Till; Herbst, Kobus; Tanser, Frank
Recent declines in adult HIV-1 incidence have followed the large-scale expansion of antiretroviral therapy and primary HIV prevention across high-burden communities of sub-Saharan Africa. Mathematical modeling suggests that HIV risk will decline disproportionately in younger adult age-groups as interventions scale, concentrating new HIV infections in those >age 25 over time. Yet, no empirical data exist to support these projections. We conducted a population-based cohort study over a 16-y period (2004 to 2019), spanning the early scale-up of antiretroviral therapy and voluntary medical male circumcision, to estimate changes in the age distribution of HIV incidence in a hyperepidemic region of KwaZulu-Natal, South Africa, where adult HIV incidence has recently declined. Median age of HIV seroconversion increased by 5.5 y in men and 3.0 y in women, and the age of peak HIV incidence increased by 5.0 y in men and 2.0 y in women. Incidence declined disproportionately among young men (64% in men 15 to 19, 68% in men 20 to 24, and 46% in men 25 to 29) and young women (44% in women 15 to 19, 24% in women 20 to 24) comparing periods pre- versus post-universal test and treat. Incidence was stable (<20% change) in women aged 30 to 39 and men aged 30 to 34. Age shifts in incidence occurred after 2012 and were observed earlier in men than in women. These results provide direct epidemiological evidence of the changing demographics of HIV risk in sub-Saharan Africa in the era of large-scale treatment and prevention. More attention is needed to address lagging incidence decline among older individuals.
PMID: 34244424
ISSN: 1091-6490
CID: 4932222

Predicting HIV Incidence in the SEARCH Trial: A Mathematical Modeling Study

Jewell, Britta L; Balzer, Laura B; Clark, Tamara D; Charlebois, Edwin D; Kwarisiima, Dalsone; Kamya, Moses R; Havlir, Diane V; Petersen, Maya L; Bershteyn, Anna
BACKGROUND:The SEARCH study provided community-based HIV and multi-disease testing and antiretroviral therapy (ART) to 32 communities in East Africa and reported no statistically significant difference in three-year HIV incidence. We used mathematical modelling to estimate the effect of control arm viral suppression and community mixing on SEARCH trial outcomes. SETTING/METHODS:Uganda and Kenya. METHODS:Using the individual-based HIV modeling software EMOD-HIV, we configured a new model of SEARCH communities. The model was parameterized using demographic, HIV prevalence, male circumcision, and viral suppression data, and calibrated to HIV prevalence, ART coverage, and population size. Using assumptions about ART scale-up in the control arm, degree of community mixing, and effect of baseline testing, we estimated comparative HIV incidence under multiple scenarios. RESULTS:Prior to the trial results, we predicted that SEARCH would report a 4-40% reduction between arms, depending on control arm ART linkage rates and community mixing. With universal baseline testing followed by rapidly expanded ART eligibility and uptake, modelled effect sizes were smaller than the study was powered to detect. Using interim viral suppression data, we estimated three-year cumulative incidence would have been reduced by up to 27% in the control arm and 43% in the intervention arm compared to a counterfactual without universal baseline testing. CONCLUSIONS:Our model suggests that the active control arm substantially reduced expected effect size and power of the SEARCH study. However, compared to a counterfactual "true control" without increased ART linkage due to baseline testing, SEARCH reduced HIV incidence by up to 43%.
PMID: 33770065
ISSN: 1944-7884
CID: 4823032

Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial

Johnston, Christine; Brown, Elizabeth R; Stewart, Jenell; Karita, Helen C Stankiewicz; Kissinger, Patricia J; Dwyer, John; Hosek, Sybil; Oyedele, Temitope; Paasche-Orlow, Michael K; Paolino, Kristopher; Heller, Kate B; Leingang, Hannah; Haugen, Harald S; Dong, Tracy Q; Bershteyn, Anna; Sridhar, Arun R; Poole, Jeanne; Noseworthy, Peter A; Ackerman, Michael J; Morrison, Susan; Greninger, Alexander L; Huang, Meei-Li; Jerome, Keith R; Wener, Mark H; Wald, Anna; Schiffer, Joshua T; Celum, Connie; Chu, Helen Y; Barnabas, Ruanne V; Baeten, Jared M
Background/UNASSIGNED:Treatment options for outpatients with COVID-19 could reduce morbidity and prevent SARS-CoV-2 transmission. Methods/UNASSIGNED:In this randomized, double-blind, three-arm (1:1:1) placebo-equivalent controlled trial conducted remotely throughout the United States, adult outpatients with laboratory-confirmed SARS-CoV-2 infection were recruited. Participants were randomly assigned to receive hydroxychloroquine (HCQ) (400 mg BID x1day, followed by 200 mg BID x9days) with or without azithromycin (AZ) (500 mg, then 250 mg daily x4days) or placebo-equivalent (ascorbic acid (HCQ) and folic acid (AZ)), stratified by risk for progression to severe COVID-19 (high-risk vs. low-risk). Self-collected nasal swabs for SARS-CoV-2 PCR, FLUPro symptom surveys, EKGs and vital signs were collected daily. Primary endpoints were: (a) 14-day progression to lower respiratory tract infection (LRTI), 28-day COVID-19 related hospitalization, or death; (b) 14-day time to viral clearance; secondary endpoints included time to symptom resolution (ClinicalTrials.gov: NCT04354428). Due to the low rate of clinical outcomes, the study was terminated for operational futility. Findings/UNASSIGNED: = 0.70). Interpretation/UNASSIGNED:Neither HCQ nor HCQ/AZ shortened the clinical course of outpatients with COVID-19, and HCQ, but not HCQ/AZ, had only a modest effect on SARS-CoV-2 viral shedding. HCQ and HCQ/AZ are not effective therapies for outpatient treatment of SARV-CoV-2 infection. Funding/UNASSIGNED:ClinicalTrials.gov number NCT04354428.
PMCID:7912360
PMID: 33681731
ISSN: 2589-5370
CID: 4809012

The impact of the program for medical male circumcision on HIV in South Africa: analysis using three epidemiological models

Korenromp, Eline L; Bershteyn, Anna; Mudimu, Edina; Weiner, Renay; Bonecwe, Collen; Loykissoonlal, Dayanund; Manuhwa, Clarence; Pretorius, Carel; Teng, Yu; Stover, John; Johnson, Leigh F
Background: South Africa began offering medical male circumcision (MMC) in 2010. We evaluated the current and future impact of this program to see if it is effective in preventing new HIV infections. Methods: The Thembisa, Goals and Epidemiological Modeling Software (EMOD) HIV transmission models were calibrated to South Africa's HIV epidemic, fitting to household survey data on HIV prevalence, risk behaviors, and proportions of men circumcised, and to programmatic data on intervention roll-out including program-reported MMCs over 2009-2017. We compared the actual program accomplishments through 2017 and program targets through 2021 with a counterfactual scenario of no MMC program. Results: The MMC program averted 71,000-83,000 new HIV infections from 2010 to 2017. The future benefit of the circumcision already conducted will grow to 496,000-518,000 infections (6-7% of all new infections) by 2030. If program targets are met by 2021 the benefits will increase to 723,000-760,000 infections averted by 2030. The cost would be $1,070-1,220 per infection averted relative to no MMC. The savings from averted treatment needs would become larger than the costs of the MMC program around 2034-2039. In the Thembisa model, when modelling South Africa's 9 provinces individually, the 9-provinces-aggregate results were similar to those of the single national model. Across provinces, projected long-term impacts were largest in Free State, KwaZulu-Natal and Mpumalanga (23-27% reduction over 2017-2030), reflecting these provinces' greater MMC scale-up. Conclusions: MMC has already had a modest impact on HIV incidence in South Africa and can substantially impact South Africa's HIV epidemic in the coming years.
PMCID:7878969
PMID: 33615145
ISSN: 2572-4754
CID: 4794172

Cost-effectiveness of point-of-care testing with task-shifting for HIV care in South Africa: a modelling study

Sharma, Monisha; Mudimu, Edinah; Simeon, Kate; Bershteyn, Anna; Dorward, Jienchi; Violette, Lauren R; Akullian, Adam; Abdool Karim, Salim S; Celum, Connie; Garrett, Nigel; Drain, Paul K
BACKGROUND:The number of people on antiretroviral therapy (ART) requiring treatment monitoring in low-resource settings is rapidly increasing. Point-of-care (POC) testing for ART monitoring might alleviate burden on centralised laboratories and improve clinical outcomes, but its cost-effectiveness is unknown. METHODS:We used cost and effectiveness data from the STREAM trial in South Africa (February, 2017-October, 2018), which evaluated POC testing for viral load, CD4 count, and creatinine, with task shifting from professional to lower-cadre registered nurses compared with laboratory-based testing without task shifting (standard of care). We parameterised an agent-based network model, EMOD-HIV, to project the impact of implementing this intervention in South Africa over 20 years, simulating approximately 175 000 individuals per run. We assumed POC monitoring increased viral suppression by 9 percentage points, enrolment into community-based ART delivery by 25 percentage points, and switching to second-line ART by 1 percentage point compared with standard of care, as reported in the STREAM trial. We evaluated POC implementation in varying clinic sizes (10-50 patient initiating ART per month). We calculated incremental cost-effectiveness ratios (ICERs) and report the mean and 90% model variability of 250 runs, using a cost-effectiveness threshold of US$500 per disability-adjusted life-year (DALY) averted for our main analysis. FINDINGS/RESULTS:POC testing at 70% coverage of patients on ART was projected to reduce HIV infections by 4·5% (90% model variability 1·6 to 7·6) and HIV-related deaths by 3·9% (2·0 to 6·0). In clinics with 30 ART initiations per month, the intervention had an ICER of $197 (90% model variability -27 to 863) per DALY averted; results remained cost-effective when varying background viral suppression, ART dropout, intervention effectiveness, and reduction in HIV transmissibility. At higher clinic volumes (≥40 ART initiations per month), POC testing was cost-saving and at lower clinic volumes (20 ART initiations per month) the ICER was $734 (93 to 2569). A scenario that assumed POC testing did not increase enrolment into community ART delivery produced ICERs that exceeded the cost-effectiveness threshold for all clinic volumes. INTERPRETATION/CONCLUSIONS:POC testing is a promising strategy to cost-effectively improve patient outcomes in moderately sized clinics in South Africa. Results are most sensitive to changes in intervention impact on enrolment into community-based ART delivery. FUNDING/BACKGROUND:National Institutes of Health.
PMID: 33347810
ISSN: 2352-3018
CID: 4726302

The aging of HIV-1 incidence in hyperendemic rural South Africa [Meeting Abstract]

Akullian, A N; Vandormael, A; Miller, J; Bershteyn, A; Wenger, E; Cuadros, D F; Tanser, F
Background: The burden of HIV in sub-Saharan Africa has aged substantially over the last decade, yet little is known about age-specific shifts in HIV incidence.
Method(s): Between 2004 and 2017, data were collected from individuals enrolled in the Africa Health Research Institute's population-based HIV cohort in rural South Africa. A population-based cohort study was conducted to quantify changes in age-specific incidence among men 15-54 and women 15-49. Poisson generalized additive models were used to test changes in the age-distribution of HIV incidence and explore potential drivers.
Result(s): We observed 3,144 HIV seroconversions among 20,388 HIV negative individuals contributing 87,882 person-years of observation from 2004-2017 (incidence rate of 3.5 per 100 person-years). The age-distribution of HIV incidence shifted older in both men (p=0.021) and women (p<0.001). Age of peak incidence increased by four years among men, from 27 (95% CI, 25-33) to 31 (95% CI, 28-34); and by three years among women, from 22 (95% CI, 21-23) to 25 (95% CI, 23-31). Incidence declined by 50% among men 15-19, IRR = 0.53 (0.33-0.82). Age-specific incidence relative to 15-19 year-olds doubled among men 30-34 years, IRR=2.30, 95% CI, 1.24 - 4.26; and increased by 50% among women 30-34 years, IRR=1.51, 95% CI, (1.09-2.05).
Conclusion(s): HIV-1 incidence shifted older over a 14-year period during scale-up of HIV treatment and prevention in a hyperepidemic South African cohort. The aging risk of HIV acquisition will require expanding demographic targets for HIV prevention beyond the youngest cohorts in high burden settings. (Figure Presented)
EMBASE:633781430
ISSN: 2161-5853
CID: 4757612

Individual and community-level benefits of PrEP in western Kenya and South Africa: Implications for population prioritization of PrEP provision

Mudimu, Edinah; Peebles, Kathryn; Mukandavire, Zindoga; Nightingale, Emily; Sharma, Monisha; Medley, Graham F; Klein, Daniel J; Kripke, Katharine; Bershteyn, Anna
BACKGROUND:Pre-exposure prophylaxis (PrEP) is highly effective in preventing HIV and has the potential to significantly impact the HIV epidemic. Given limited resources for HIV prevention, identifying PrEP provision strategies that maximize impact is critical. METHODS:We used a stochastic individual-based network model to evaluate the direct (infections prevented among PrEP users) and indirect (infections prevented among non-PrEP users as a result of PrEP) benefits of PrEP, the person-years of PrEP required to prevent one HIV infection, and the community-level impact of providing PrEP to populations defined by gender and age in western Kenya and South Africa. We examined sensitivity of results to scale-up of antiretroviral therapy (ART) and voluntary medical male circumcision (VMMC) by comparing two scenarios: maintaining current coverage ("status quo") and rapid scale-up to meet programmatic targets ("fast-track"). RESULTS:The community-level impact of PrEP was greatest among women aged 15-24 due to high incidence, while PrEP use among men aged 15-24 yielded the highest proportion of indirect infections prevented in the community. These indirect infections prevented continue to increase over time (western Kenya: 0.4-5.5 (status quo); 0.4-4.9 (fast-track); South Africa: 0.5-1.8 (status quo); 0.5-3.0 (fast-track)) relative to direct infections prevented among PrEP users. The number of person-years of PrEP needed to prevent one HIV infection was lower (59 western Kenya and 69 in South Africa in the status quo scenario; 201 western Kenya and 87 in South Africa in the fast-track scenario) when PrEP was provided only to women compared with only to men over time horizons of up to 5 years, as the indirect benefits of providing PrEP to men accrue in later years. CONCLUSIONS:Providing PrEP to women aged 15-24 prevents the greatest number of HIV infections per person-year of PrEP, but PrEP provision for young men also provides indirect benefits to women and to the community overall. This finding supports existing policies that prioritize PrEP use for young women, while also illuminating the community-level benefits of PrEP availability for men when resources permit.
PMID: 33382803
ISSN: 1932-6203
CID: 4731942